157 results about "Squamous Carcinomas" patented technology

The invention relates to a composition for identifying oral squamous cell carcinoma based on saliva sample detection and application, and belongs to the technical field of molecular biology. The composition provided by the invention is used for identifying the oral squamous cell carcinoma by detecting the expression of SNORD52 and / or SNORD65 in a saliva sample; the composition comprises a specific reverse transcription stem-loop primer, a specific detection forward primer, a specific detection probe and a universal reverse primer. According to the composition disclosed by the invention, the expression of SNORD52 and / or SNORD65 in a saliva sample is detected, and a binomial logistic regression model is combined to perform auxiliary judgment on the oral squamous cell carcinoma, so that the composition has relatively high sensitivity and specificity, and the identification accuracy of the oral squamous cell carcinoma can be improved. The invention further provides a kit containing the composition, a detection object of the kit is a saliva sample, and the kit has the advantages of being small in sample dosage, noninvasive in sampling, convenient, rapid, small in risk and the like.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention provides a micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and a preparation method thereof, and relates to the technical field of micro-fluidic chips, the chip comprises a four-layer structure: the first layer is a closed layer, the second layer is a culture solution / drug pool layer (containing a concentration gradient injection channel and a slow flow channel), the third layer is a matrix culture pool layer, and the fourth layer is a matrix culture pool layer. The fourth layer is a matrigel inflow layer (containing an S-shaped flow channel); the second layer and the third layer are integrally formed, and all the layers are connected through oxygen plasma welding; the problems that in the prior art, matrigel is prone to shifting, drug gradient regulation and control is poor, operation is tedious, and adaptability is insufficient are solved, the matrigel and organoids can be stably fixed, the drug concentration gradient can be precisely regulated and controlled, the nutrition supply efficiency is enhanced, the structural integration level and operation convenience are improved, and the application prospect is wide. The method is suitable for oral squamous cell carcinoma organoid culture, drug screening and tumor mechanism research.

The invention provides equipment, a method and a system for evaluating prognosis of cervical cancer, squamous carcinoma and adenocarcinoma and application of the equipment, the method and the system, and belongs to the technical field of medical evaluation. Two biomarkers, namely adenylate kinase 4 and cavernous malformation 2 protein, for evaluating prognosis of cervical squamous cell carcinoma and adenocarcinoma are obtained through multivariate statistical analysis, difference screening, COX regression analysis and other biosignal analysis methods. Based on the biomarker, evaluation equipment, a computer execution method, a computer system and the like for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma are constructed, and the evaluation equipment, the computer execution method, the computer system and the like are used for accurately judging the prognosis condition of a cervical cancer patient.

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The invention belongs to the technical field of biological medicine, and provides self-assembled polypeptide targeting mitochondria, a preparation method and application of the self-assembled polypeptide, a self-assembled polypeptide microneedle patch and a preparation method of the self-assembled polypeptide microneedle patch. According to the self-assembly polypeptide of the targeted mitochondria, the amino acid sequence is GFFGKXRXKXRX, and X represents cyclohexyl alanine. A targeting peptide (Mito) sequence KXRXKXRX can recognize cell mitochondria in a targeting manner, a self-assembly sequence GFFG is introduced to an N terminal of the Mito sequence KXRXKXRX, and the targeting peptide sequence is endowed with a self-assembly capability, so that the self-assembly polypeptide can cause morphological function abnormality of mitochondria in tumor cells, the tumor cells are killed, and inhibition of the tumor cells is realized. The self-assembled polypeptide disclosed by the invention is applied to treatment of tumor cells through in-situ administration of the self-assembled polypeptide microneedle patch. Oral squamous cell carcinoma serves as a highly proliferated tumor cell, rapid proliferation of the oral squamous cell carcinoma needs a large amount of energy supply for mitochondria, and therefore attacking of the mitochondria can serve as an effective treatment target.

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The invention relates to the field of biomedicine, and discloses an expiration marker combination for diagnosing oral squamous cell carcinoma as well as application and a screening method of the expiration marker combination. Wherein the expiration marker combination comprises 29 oral expiration markers, a scoring model is constructed through the relative content of VOC signals of the expiration markers, the scoring model can be used for evaluating the oral squamous cell carcinoma risk of a patient, and the invention further discloses a screening method of the expiration marker combination. According to the screening method, a multi-algorithm feature union set strategy is adopted, the algorithm advantages of UTest, Boruta, LGBM, RF and the like are integrated, the limitation of a single algorithm is overcome, and the OSCC related expiration markers are recognized to the maximum extent. The core marker screening basis is clear, the PTR-TOF-MS detection process is standard, an interpretable verification mechanism is constructed, clinical popularization is facilitated, invasive biopsy dependence is reduced, diagnosis efficiency and patient compliance are improved, and important clinical and social values are achieved.

The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

The invention relates to the technical field of image processing, and discloses an oral squamous cell carcinoma invasion depth measurement method and system based on artificial intelligence. The method comprises the steps of performing standardization processing on oral tissue slices through a three-dimensional preprocessing algorithm to obtain a tumor mask image and a confidence map, then performing multipoint sampling deployment of a virtual measurement agent on the tumor surface, detecting feasibility of an invasion path by using a tissue resistance model, performing multi-branch feature extraction and deep regression calculation through an OSCC-DepthNet network, and finally obtaining the tumor mask image and the confidence map through the OSCC-DepthNet network. And obtaining an invasion path and a depth value of each agent, fusing multi-agent measurement results by adopting a confidence weighting algorithm, and outputting an oral squamous cell carcinoma invasion depth value and an uncertainty estimation value. The technical problems that an existing oral squamous cell carcinoma invasion depth measurement method is insufficient in three-dimensional space measurement capacity, too high in calculation complexity, poor in real-time performance and lack of an effective uncertainty quantification mechanism are solved.

The invention discloses application of LncRNA GSEC in preparation of a medicine for treating oral squamous cell carcinoma, and relates to the technical field of biological medicine. The nucleotide sequence of the LncRNA GSEC is shown as SEQ ID NO: 1, the medicine contains an active component capable of inhibiting expression or functions of the LncRNA GSEC, the active component is one or more of siRNA, shRNA or a small-molecule inhibitor, and the medicine is used for inhibiting proliferation, migration and / or invasion of OSCC cells and / or inducing cell apoptosis. The specific high expression of the LncRNA GSEC in oral squamous cell carcinoma tissues and cells is disclosed for the first time, and the expression level of the LncRNA GSEC is remarkably and positively correlated with adverse clinical parameters such as tumor T staging and lymph node metastasis, so that the LncRNA GSEC is proved to serve as a novel molecular target with clinical application potential.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

This invention relates to the interdisciplinary field of cell biology, experimental oncology, and translational medicine, specifically to a cancer-associated fibroblast cell line, its construction method, and its applications. This invention fills the research gap in mouse-derived oral squamous cell carcinoma-associated fibroblast cell line models and provides a method for constructing such a cell line. Through the inverted adherent culture and enzymatic digestion methods of this invention, a mouse-derived oral squamous cell carcinoma-associated fibroblast cell line with a clear origin, high purity, and long-term phenotypic and functional stability can be obtained. This allows for the establishment of a cryopreservable and resuscitable mouse oral squamous cell carcinoma-associated fibroblast cell bank, providing technical support for research related to the tumor microenvironment and immunotherapy.

The application discloses a Campylobacter for treating oral squamous cell carcinoma and application thereof. It is found by the application that a Campylobacter showae strain has significant anti-tumor activity on a mouse model of oral squamous cell carcinoma, can significantly inhibit tumor growth, and promote the formation of tertiary lymphoid structures in oral squamous cell carcinoma. Therefore, the Campylobacter showae strain and a composition thereof can be used for preparing products for preventing, treating, adjuvant treating or prognosis nursing oral squamous cell carcinoma, and provide a new microbial intervention strategy for oral squamous cell carcinoma and related immunotherapy.

The application discloses a new use of a biomarker AF131217.1, and particularly discloses application of the biomarker AF131217.1 in diagnosis and treatment of oral squamous cell carcinoma. The application proves that the AF131217.1 can be used as a diagnostic marker and a therapeutic target of the oral squamous cell carcinoma. The oral squamous cell carcinoma can be diagnosed by detecting the expression level of the AF131217.1. The AF131217.1 is used as a drug target to assist clinical operation treatment by inhibiting the expression of the AF131217.1, so that the cure rate of patients is improved, and the life quality of the patients is improved.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The present invention relates to a kit for detecting biomarkers and differentiating histological subtypes of non-small cell lung cancer. The detection biomarkers of the present invention include detecting the methylation degree of one or more of human chromosomes chr20:47444720-47444924, chr20:47444217-47444339 or chr20:47444014-47444136 and their combinations. Through high-throughput sequencing and locus-specific methylation fluorescence quantitative PCR methods, the present invention has discovered methylation gene sequences that can distinguish adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The present invention discloses an image processing method for oral mucosal squamous cell carcinoma, which relates to the technical field of image processing. The method comprises the following steps: inputting #imgabs0# into a first semantic segmentation model, inputting #imgabs1# into a second semantic segmentation model, and obtaining a saliva mask and a local positive lesion mask #imgabs2#; obtaining a transition mask #imgabs3#; calculating boundary mutation strength, constructing a boundary-guided diffusion map #imgabs4# according to the boundary mutation strength, using #imgabs5# to segment a local positive lesion mask #imgabs7# from #imgabs6#, and merging #imgabs8# and #imgabs9# to obtain an overall lesion mask. The present invention can achieve more complete and accurate segmentation of oral mucosal squamous cell carcinoma lesion areas under conditions of strong reflective occlusion and complex background.

The application belongs to the field of tumor molecular diagnosis and targeted therapy, and specifically finds lncRNA RP11-499F3.2 which is significantly highly expressed in head and neck cancer through bioinformatics analysis of TCGA data; it is verified through clinical samples that the expression level of RP11-499F3.2 in head and neck squamous cell carcinoma is significantly higher than that in paracancerous tissues, and is closely related to the clinical prognosis of patients with head and neck squamous cell carcinoma; it is found through functional experiments that high expression of RP11-499F3.2 can promote the in-vitro proliferation, migration and invasion of head and neck squamous cell carcinoma cells; meanwhile, it is also found that RP11-499F3.2 can promote the drug resistance of head and neck squamous cell carcinoma cells to cetuximab; the disclosed lncRNA RP11-499F3.2 helps to reveal the new pathogenesis of head and neck cancer, provides a new tumor marker for the prognosis monitoring of head and neck cancer, and provides a new idea for the clinical treatment of head and neck cancer.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention relates to a polyethylene glycol medicine as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salt thereof, an intermediate compound as shown in a formula II-XX, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibition effect on tumors such as breast cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

The invention discloses an application of a TNFRSF12A inhibitor in preparation of a medicine for treating oral squamous cell carcinoma. Based on single cell transcriptome data, oral squamous cell canceration related tissues are divided into four tissue ecological subtypes, and a tumor sample is divided into two subtypes ET3 and ET4. The ET3 subtype is a lymphocyte infiltration type, and shows CD8 + T cell infiltration, immune activation pathway activity enhancement and high expression of CD3, CD8A and PDCD1; the ET4 subtype is a lymphocyte rejection type, is enriched with COL1A1 + fibroblasts, and is accompanied by high expression of TNFRSF12A, COL1A1 and CD276. According to the application disclosed by the invention, the expression of the TNFRSF12A in the ET4 subtype is obviously improved, in-vivo experiments prove that knockout or blocking of the TNFRSF12A can promote lymphatic T cell infiltration and inhibit tumor growth, and a stronger inhibition effect is shown when the knockout or blocking of the TNFRSF12A is combined with an immune checkpoint inhibitor. The invention provides a system for typing oral squamous cell carcinoma.

The invention belongs to the technical field of medicines, and particularly discloses an oral squamous cell carcinoma inhibitor and application thereof. The inhibitor takes rutin as an active component. In-vitro experiments prove that rutin can significantly inhibit proliferation, clone formation, migration and invasion ability of OSCC cells in a dose-dependent manner, and effectively induce cell apoptosis. The action mechanism of the rutin is as follows: the rutin can directly target STAT3 protein and inhibit phosphorylation of the STAT3 protein so as to regulate and control a downstream BCL2 / CASP3 apoptosis pathway, thereby playing a role in treating OSCC. Molecular docking results further show that rutin and STAT3 have strong binding capacity. The invention discloses a new application of rutin as an STAT3 inhibitor in treating oral squamous cell carcinoma, and provides a new strategy and a candidate compound for developing high-efficiency and low-toxicity OSCC treatment medicines.

The invention relates to an exosome and application thereof, and belongs to the technical field of tumor immunotherapy. According to the scheme, the repolarization effect of exosomes secreted after oral squamous cell carcinoma cells are stimulated by phenformin on M2 macrophages is researched, miRNA-17 and / or miRNA-20 capable of acting on STAT3 mRNA in the M2 macrophages are / is found, and it is found through further research that miRNA-17 and / or miRNA-20 can act on 3 '-UTR areas of STAT3 mRNA in the M2 macrophages, so that repolarization of the M2 macrophages is promoted. According to the application, deep research is carried out from the perspective of the action pathway of miRNA, and a brand new technical route which is feasible for tumor immunotherapy is provided through experimental verification of different levels, so that the application has a wide clinical application prospect and a huge commercial value.

The invention discloses an application of a CCR6 antagonist in treatment of oral squamous cell carcinoma. The invention belongs to the field of biomedicine, and particularly relates to application of a CCR6 antagonist in treatment of oral squamous cell carcinoma. The invention provides an application of a substance for inhibiting CCR6 gene expression or a substance for inhibiting CCR6 protein activity or a substance for reducing CCR6 protein content in preparation of products of drugs for treating oral squamous cell carcinoma or / and preventing oral squamous cell carcinoma or / and preparing drugs for inhibiting tumor cell activity or anti-tumor activity. By adopting the CCR6 antagonist HY-151435, the normal high expression of CCR6 in OSCC can be blocked, and the recruitment of immunosuppressive cells of tumor-related regulatory T cells (Tregs) is reduced, so that the immunosuppressive microenvironment is reversed.

This invention discloses a method and system for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma, belonging to the field of two-dimensional image processing technology for oral squamous cell carcinoma. It aims to improve the accuracy and stability of early screening for oral squamous cell carcinoma. The invention acquires oral image data, labels the acquired images according to pre-set classification standards to obtain training and testing sets; preprocesses the oral image data to obtain preprocessed training and testing sets; performs data augmentation on the oral image data in the training set to obtain a data-augmented training set; constructs an image feature extraction model based on a convolutional neural network; and trains the convolutional neural network-based image feature extraction model using supervised learning to obtain a trained convolutional neural network-based image feature extraction model for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma.